## Martin Orban

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2313029/publications.pdf

Version: 2024-02-01

257450 214800 2,602 105 24 47 h-index citations g-index papers 112 112 112 3145 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Transcatheter edge-to-edge mitral valve repair in mitral regurgitation: current status and future prospects. Expert Review of Medical Devices, 2023, 20, 99-108.	2.8	7
2	ADP-induced platelet reactivity and bleeding events in patients with acute myocardial infarction complicated by cardiogenic shock. Platelets, 2022, 33, 371-380.	2.3	4
3	Choosing the right potent P2Y12-receptor inhibitor in East Asians with acute myocardial infarction and percutaneous coronary intervention – Editorial on Ticagrelor versus Prasugrel in patients with acute myocardial infarction. International Journal of Cardiology, 2022, 347, 17-18.	1.7	O
4	Impact of asymmetric tethering on outcomes after edge-to-edge mitral valve repair for secondary mitral regurgitation. Clinical Research in Cardiology, 2022, 111, 869-880.	3 <b>.</b> 3	4
5	Hybrid Surgery for Severe Mitral Valve Calcification: Limitations and Caveats for an Open Transcatheter Approach. Medicina (Lithuania), 2022, 58, 93.	2.0	1
6	Cardiohepatic Syndrome Is Associated With Poor Prognosis in Patients Undergoing Tricuspid Transcatheter Edge-to-Edge Valve Repair. JACC: Cardiovascular Interventions, 2022, 15, 179-189.	2.9	22
7	Intracranial haemorrhage in adult patients on venoarterial extracorporeal membrane oxygenation. European Heart Journal: Acute Cardiovascular Care, 2022, 11, 303-311.	1.0	4
8	Manual Compression versus Suture-Mediated Closure Device Technique for VA-ECMO Decannulation. Journal of Interventional Cardiology, 2022, 2022, 1-6.	1.2	2
9	Durability of benefit after transcatheter tricuspid valve intervention: insights from actigraphy. European Journal of Heart Failure, 2022, 24, 1293-1301.	7.1	6
10	Transcatheter Aortic Valve Replacement with the Self-Expandable Core Valve Evolut Prosthesis Using the Cusp-Overlap vs. Tricusp-View. Journal of Clinical Medicine, 2022, 11, 1561.	2.4	15
11	Assessment of sex- and age-dependency of risk factors for intimal hyperplasia in heart transplant patients using the high resolution of optical coherence tomography. International Journal of Cardiology, 2022, , .	1.7	0
12	Percutaneous Transvalvular Microaxial Flow Pump Support in Cardiology. Circulation, 2022, 145, 1254-1284.	1.6	29
13	Incidence and Outcome of Patients with Cardiogenic Shock and Detection of Herpes Simplex Virus in the Lower Respiratory Tract. Journal of Clinical Medicine, 2022, 11, 2351.	2.4	1
14	Propofol versus midazolam sedation in patients with cardiogenic shock - an observational propensity-matched study. Journal of Critical Care, 2022, 71, 154051.	2.2	5
15	Systolic or diastolic CT image acquisition for transcatheter aortic valve replacement – An outcome analysis. Journal of Cardiovascular Computed Tomography, 2022, 16, 423-430.	1.3	4
16	Implementation of a Clinical Trial Recruitment Support System Based on Fast Healthcare Interoperability Resources (FHIR) in a Cardiology Department. Studies in Health Technology and Informatics, 2022, , .	0.3	2
17	Outcome of patients treated with extracorporeal life support in cardiogenic shock complicating acute myocardial infarction: 1-year result from the ECLS-Shock study. Clinical Research in Cardiology, 2021, 110, 1412-1420.	3.3	24
18	Noncanonical Effects of Oral Thrombin and Factor Xa Inhibitors in Platelet Activation and Arterial Thrombosis. Thrombosis and Haemostasis, 2021, 121, 122-130.	3.4	8

#	Article	IF	CITATIONS
19	Anatomy and Outcome of Secondary Mitral Regurgitation Subtypes Undergoing Transcatheter Mitral Valve Edge-to-Edge Repair. JACC: Cardiovascular Interventions, 2021, 14, 110-111.	2.9	6
20	The multiple options of left atrial and ventricular venting during veno-arterial extra-corporeal membrane oxygenation: practical considerations. European Heart Journal, 2021, 42, 2399-2400.	2.2	5
21	Venoarterial extracorporeal membrane oxygenation as bridge to effective treatment in a 19-year-old woman with acute adrenal crisis: a case report. European Heart Journal - Case Reports, 2021, 5, ytab031.	0.6	1
22	Pembrolizumab-induced myocarditis in a patient with malignant mesothelioma: plasma exchange as a successful emerging therapyâ€"case report. Translational Lung Cancer Research, 2021, 10, 1039-1046.	2.8	18
23	Veno-arterial extracorporeal membrane oxygenation (ECMO) in patients with cardiogenic shock: rationale and design of the randomised, multicentre, open-label EURO SHOCK trial. EuroIntervention, 2021, 16, e1227-e1236.	3.2	56
24	Treatment of acute cardiac tamponade: A retrospective analysis of classical intermittent versus continuous pericardial drainage. IJC Heart and Vasculature, 2021, 32, 100722.	1.1	2
25	Percutaneous edgeâ€toâ€edge repair of severe mitral regurgitation using the <scp>MitraClip XTR</scp> versus <scp>NTR</scp> system. Clinical Cardiology, 2021, 44, 708-714.	1.8	12
26	The lack of evidence-based therapeutic strategies for left ventricular unloading during venoarterial extracorporeal membrane oxygenation therapy calls for randomized trials. European Heart Journal, 2021, 42, 3105-3106.	2.2	3
27	New challenges in cardiac intensive care units. Clinical Research in Cardiology, 2021, 110, 1369-1379.	3.3	5
28	Clopidogrel vs. prasugrel vs. ticagrelor in patients with acute myocardial infarction complicated by cardiogenic shock: a pooled IABP-SHOCK II and CULPRIT-SHOCK trial sub-analysis. Clinical Research in Cardiology, 2021, 110, 1493-1503.	3.3	3
29	Combined extracorporeal membrane oxygenation and microaxial pump—when left ventricular preload is too low to unload in cardiogenic shock. Health Science Reports, 2021, 4, e321.	1.5	3
30	Percutaneous dilatational tracheotomy in high-risk ICU patients. Annals of Intensive Care, 2021, 11, 116.	4.6	3
31	Interventional Snare Procedure to Lift a Balloon-Expandable TAVR Impeding a Mechanical Bi-Leaflet Mitral Valve. JACC: Cardiovascular Interventions, 2021, 14, e189-e190.	2.9	0
32	Mortality in Cardiogenic Shock Patients Is Predicted by Pao 2/Fio 2 (Horowitz Index) Measured on ICU After Venoarterial Extracorporeal Membrane Oxygenation Implantation., 2021, 3, e0540.		5
33	Extracorporeal life support in therapy-refractory cardiocirculatory failure: looking beyond 30 days. Interactive Cardiovascular and Thoracic Surgery, 2021, 32, 607-615.	1.1	4
34	How exercise can deteriorate the clinical course of an ARVC patient: a case report. European Heart Journal - Case Reports, 2021, 5, ytab417.	0.6	2
35	Treatment of acute pericardial tamponade with a high-vacuum drainage system. Clinical Research in Cardiology, 2020, 109, 263-265.	3.3	3
36	Ten things ICU specialists need to know about new valvular procedures in interventional cardiology. Intensive Care Medicine, 2020, 46, 102-106.	8.2	6

#	Article	IF	Citations
37	Recent advances in patient selection and devices for transcatheter edge-to-edge mitral valve repair in heart failure. Expert Review of Medical Devices, 2020, 17, 93-102.	2.8	6
38	Smoking and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients: a substudy from the randomized TROPICAL-ACS trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 372-381.	3.0	7
39	Left Ventricular Unloading Is Associated With Lower Mortality in Patients With Cardiogenic Shock Treated With Venoarterial Extracorporeal Membrane Oxygenation. Circulation, 2020, 142, 2095-2106.	1.6	269
40	Tricuspid regurgitation and right ventricular dysfunction after cardiac device implantation – Is it time for intra-procedural TEE-guided lead implantation?. International Journal of Cardiology, 2020, 321, 131-132.	1.7	3
41	Long-Term Clinical Outcome of Cardiogenic Shock Patients Undergoing Impella CP Treatment vs. Standard of Care. Journal of Clinical Medicine, 2020, 9, 3803.	2.4	14
42	Prevention and treatment of pulmonary congestion in patients undergoing venoarterial extracorporeal membrane oxygenation for cardiogenic shock. European Heart Journal, 2020, 41, 3753-3761.	2.2	48
43	Update on Weaning from Veno-Arterial Extracorporeal Membrane Oxygenation. Journal of Clinical Medicine, 2020, 9, 992.	2.4	45
44	Transcatheter Edge-to-Edge Tricuspid Repair for Severe Tricuspid Regurgitation Reduces Hospitalizations for HeartÂFailure. JACC: Heart Failure, 2020, 8, 265-276.	4.1	44
45	Isoflurane Sedation in Patients Undergoing Venoarterial Extracorporeal Membrane Oxygenation Treatment for Cardiogenic Shock—An Observational Propensity-Matched Study. , 2020, 2, e0086.		11
46	Watch out for ST-elevation myocardial infarction: a case report of ST-elevation in single-lead electrocardiogram tracing of a smartwatch. European Heart Journal - Case Reports, 2020, 4, 1-4.	0.6	11
47	Aetiologyâ€based clinical scenarios predict outcomes of transcatheter edgeâ€toâ€edge tricuspid valve repair of functional tricuspid regurgitation. European Journal of Heart Failure, 2019, 21, 1117-1125.	7.1	29
48	Gender and Outcomes following Guided De-Escalation of Antiplatelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Gender Substudy. Thrombosis and Haemostasis, 2019, 119, 1527-1538.	3.4	7
49	Transcatheter edge-to-edge mitral valve repair in functional mitral regurgitation: patient selection according to MITRA-FR and COAPT. Journal of Thoracic Disease, 2019, 11, S1966-S1968.	1.4	О
50	Physical activity tracking in correlation to conventional heart failure monitoring assessing improvements after transcatheter mitral and tricuspid valve repair. European Journal of Heart Failure, 2019, 21, 943-945.	7.1	7
51	Diurnal Variability of On-Treatment Platelet Reactivity in Clopidogrel versus Prasugrel Treated Acute Coronary Syndrome Patients: A Pre-Specified TROPICAL-ACS Sub-Study. Thrombosis and Haemostasis, 2019, 119, 660-667.	3.4	12
52	Extracorporeal Life Support in Cardiogenic Shock Complicating Acute Myocardial Infarction. Journal of the American College of Cardiology, 2019, 73, 2355-2357.	2.8	79
53	Impact of Transcatheter Tricuspid Valve Repair for Severe Tricuspid Regurgitation on KidneyÂand Liver Function. JACC: Cardiovascular Interventions, 2019, 12, 1413-1420.	2.9	54
54	Uncommon cause of progressive dyspnoea 12 years after coronary artery bypass surgery. European Heart Journal, 2019, 40, 3950-3950.	2.2	0

#	Article	IF	CITATIONS
55	Percutaneous Decannulation Instead of Surgical Removal for Weaning After Venoarterial Extracorporeal Membrane Oxygenation—A Crossed Perclose ProGlide Closure Device Technique Using a Hemostasis Valve Y Connector. , 2019, 1, e0018.		20
56	Safety of Percutaneous Dilatational Tracheotomy in Patients on Dual Antiplatelet Therapy and Anticoagulation., 2019, 1, e0050.		9
57	Transcatheter Edge-to-Edge Repair for Tricuspid Regurgitation Is Associated With Right Ventricular Reverse Remodeling in Patients With Right-SidedÂHeart Failure. JACC: Cardiovascular Imaging, 2019, 12, 559-560.	5.3	43
58	Transcatheter treatment of functional mitral regurgitation after MITRA-FR and COAPT – Patient selection is most important. International Journal of Cardiology, 2019, 288, 57-58.	1.7	6
59	Clinical impact of elevated tricuspid valve inflow gradients after transcatheter edge-to-edge tricuspid valve repair. EuroIntervention, 2019, 15, e1057-e1064.	3.2	9
60	Sixâ€month outcome after transcatheter edgeâ€toâ€edge repair of severe tricuspid regurgitation in patients with heart failure. European Journal of Heart Failure, 2018, 20, 1055-1062.	7.1	76
61	Edge-to-edge mitral valve repair: solid data and a prosperous future. Heart, 2018, 104, 280-281.	2.9	4
62	Platelet Reactivity and Early Outcomes after Transfemoral Aortic Valve Implantation. Thrombosis and Haemostasis, $2018,118,1832\text{-}1838.$	3.4	15
63	Physical Activity and Noninvasive Cardiac Output as Novel Clinical Endpoints After Transcatheter Valve Repair for Severe Tricuspid Regurgitation. JACC: Cardiovascular Interventions, 2018, 11, 2127-2129.	2.9	10
64	Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation Using the Triple-Orifice Technique Versus the Bicuspidalization Technique. JACC: Cardiovascular Interventions, 2018, 11, 1790-1792.	2.9	39
65	Percutaneous treatment of functional mitral regurgitation – Awaiting results of COAPT and MITRA-FR. International Journal of Cardiology, 2018, 269, 89-90.	1.7	1
66	Outcomes Following Mitraclip in Advanced Heart Failure Patients: A Meta-Analysis. Journal of Heart and Lung Transplantation, 2018, 37, S201.	0.6	0
67	Long-Term Outcomes After MitraClip Implantation According to the Presence or Absence of EVEREST Inclusion Criteria. American Journal of Cardiology, 2017, 119, 1255-1261.	1.6	57
68	Predictors for longâ€term survival after transcatheter edgeâ€toâ€edge mitral valve repair. Journal of Interventional Cardiology, 2017, 30, 226-233.	1.2	47
69	Transcatheter Treatment of Severe Tricuspid Regurgitation Using the Edge-to-Edge Repair Technique in the Presence and Absence of Pacemaker Leads. JACC: Cardiovascular Interventions, 2017, 10, 2014-2016.	2.9	27
70	Uncommon cause of dyspnoea after percutaneous closure of the left atrial appendage. European Heart Journal, 2017, 38, 2912-2912.	2.2	1
71	A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Thrombosis and Haemostasis, 2017, 117, 188-195.	3.4	36
72	Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet, The, 2017, 390, 1747-1757.	13.7	443

#	Article	IF	CITATIONS
73	Transcatheter edge-to-edge mitral valve repair in heart failure. Minerva Cardiology and Angiology, 2017, 65, 314-320.	0.7	3
74	Transcatheter treatment of severe tricuspid regurgitation using the edge-to-edge repair technique. EuroIntervention, 2017, 12, e1837-e1844.	3.2	63
75	TCT-87 Transcatheter treatment of severe tricuspid regurgitation using the MitraClip $\hat{A}^{\otimes}$ system: 30-day clinical results in 13 consecutive patients Journal of the American College of Cardiology, 2016, 68, B35-B36.	2.8	2
76	Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study. Platelets, 2016, 27, 796-804.	2.3	11
77	Impact of the bioresorbable vascular scaffold surface area on on-treatment platelet reactivity. Platelets, 2016, 27, 446-451.	2.3	4
78	Established interventions for mitral valve regurgitation. Herz, 2016, 41, 19-25.	1.1	12
79	Platelet function and coagulation in patients with STEMI and peri-interventional clopidogrel plus heparin vs. prasugrel plus bivalirudin therapy (BRAVE 4 substudy). Thrombosis Research, 2016, 137, 72-78.	1.7	6
80	ADP receptor antagonists in patients with acute myocardial infarction complicated by cardiogenic shock: a post hoc IABP-SHOCK II trial subgroup analysis. EuroIntervention, 2016, 12, e1395-e1403.	3.2	19
81	Longâ€Term Outcome of Patients with Severe Biventricular Heart Failure and Severe Mitral Regurgitation After Percutaneous Edgeâ€toâ€Edge Mitral Valve Repair. Journal of Interventional Cardiology, 2015, 28, 164-171.	1.2	31
82	Predictors of antiplatelet response to prasugrel during maintenance treatment. Platelets, 2015, 26, 53-58.	2.3	22
83	Reply. Journal of the American College of Cardiology, 2015, 65, 2154.	2.8	24
84	The impact of therapeutic hypothermia on on-treatment platelet reactivity and clinical outcome in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction: Results from the ISAR-SHOCK registry. Thrombosis Research, 2015, 136, 87-93.	1.7	27
85	Kindlin-3–mediated integrin adhesion is dispensable for quiescent but essential for activated hematopoietic stem cells. Journal of Experimental Medicine, 2015, 212, 1415-1432.	8.5	26
86	Acute and Midterm Outcome After MitraClip Therapy in Patients With Severe Mitral Regurgitation and Left Ventricular Dysfunction. American Journal of Cardiology, 2015, 116, 749-756.	1.6	23
87	Kindlin-3–mediated integrin adhesion is dispensable for quiescent but essential for activated hematopoietic stem cells. Journal of Cell Biology, 2015, 210, 2105OIA171.	5.2	0
88	Percutaneous edgeâ€toâ€edge repair of the mitral valve in patients with degenerative versus functional mitral regurgitation. Catheterization and Cardiovascular Interventions, 2014, 84, 137-146.	1.7	40
89	Aspirin Treatment and Outcomes After Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2014, 64, 863-871.	2.8	88
90	TCT-799 Predictors Of Long Term Outcome In Heart Failure Patients With Very Low Left Ventricular Ejection Fraction And Severe Mitral Regurgitation After Percutaneous Edge To Edge Mitral Valve Repair. Journal of the American College of Cardiology, 2014, 64, B234.	2.8	0

#	Article	IF	CITATIONS
91	Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. Thrombosis and Haemostasis, 2014, 112, 1190-1197.	3.4	27
92	Dangerous liaison: successful percutaneous edge-to-edge mitral valve repair in patients with end-stage systolic heart failure can cause left ventricular thrombus formation. EuroIntervention, 2014, 10, 253-259.	3.2	18
93	Platelet Function Testing in Patients with Acute Coronary Syndrome. Journal of Cardiovascular Translational Research, 2013, 6, 371-377.	2.4	6
94	Bleeding and Thrombosis Risk Matters. JACC: Cardiovascular Interventions, 2013, 6, 864-866.	2.9	1
95	Left ventricular thrombus formation after successful percutaneous edge-to-edge mitral valve repair. European Heart Journal, 2013, 34, 942-942.	2.2	8
96	Antiplatelet efficacy of prasugrel in patients with high on-clopidogrel treatment platelet reactivity and a history of coronary stenting. Thrombosis and Haemostasis, 2013, 109, 517-254.	3.4	12
97	Three-dimensional transoesophageal echocardiography for the assessment of clip attachment to the leaflets in percutaneous edge-to-edge repair of the mitral valve. EuroIntervention, 2013, 8, 1379-1387.	3.2	22
98	Time does not heal all wounds: very late stent thrombosis eight years after implantation of a sirolimus-eluting stent due to positive remodelling, saccular evaginations and marked vascular inflammation. EuroIntervention, 2013, 9, 412-413.	3.2	1
99	A novel role of sphingosine 1-phosphate receptor S1pr1 in mouse thrombopoiesis. Journal of Experimental Medicine, 2012, 209, 2165-2181.	8.5	151
100	Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor. Platelets, 2012, 23, 395-398.	2.3	13
101	A novel role of sphingosine 1-phosphate receptor S1pr1 in mouse thrombopoiesis. Journal of General Physiology, 2012, 140, i11-i11.	1.9	2
102	A novel role of sphingosine 1-phosphate receptor S1pr1 in mouse thrombopoiesis. Journal of Cell Biology, 2012, 199, i7-i7.	5.2	0
103	Massive thrombus burden with recurrence of intracoronary thrombosis early after stenting and delayed onset of prasugrel action in a patient with ST-elevation myocardial infarction and cardiac shock. Thrombosis and Haemostasis, 2011, 106, 555-558.	3.4	7
104	ISCOMATRIX Adjuvant Induces Efficient Cross-Presentation of Tumor Antigen by Dendritic Cells via Rapid Cytosolic Antigen Delivery and Processing via Tripeptidyl Peptidase II. Journal of Immunology, 2009, 182, 1253-1259.	0.8	91
105	Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model. Gut, 2007, 56, 1275-1282.	12.1	70